| 04/30/2026 7:30 AM | Acrivon Therapeutics (1781174) Filer | Form DEF 14A | |
| 04/30/2026 7:32 AM | Acrivon Therapeutics (1781174) Filer | Form DEFA14A | |
| 04/30/2026 7:33 AM | Acrivon Therapeutics (1781174) Filer | Form ARS | |
| 04/23/2026 3:28 PM | Acrivon Therapeutics (1781174) Issuer Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund II, L.P. (1825376) Reporting Shah Rajeev M. (1619841) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/23/2026 3:29 PM | Acrivon Therapeutics (1781174) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13D/A | |
| 04/21/2026 4:05 PM | Acrivon Therapeutics (1781174) Issuer Miller Mary (1841088) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/23/2026 3:28 PM | Acrivon Therapeutics (1781174) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13D/A | |
| 03/19/2026 6:41 AM | Acrivon Therapeutics (1781174) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/19/2026 6:21 AM | Acrivon Therapeutics (1781174) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/19/2026 6:10 AM | Acrivon Therapeutics (1781174) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/02/2026 3:30 PM | Acrivon Therapeutics (1781174) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for ACRV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/27/2026 8:00 AM | Acrivon Therapeutics (1781174) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/24/2026 3:12 PM | Acrivon Therapeutics (1781174) Issuer Blume-Jensen Peter (1950499) Reporting Masson Kristina (1950501) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 3:10 PM | Acrivon Therapeutics (1781174) Issuer Devroe Eric (1950573) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 3:11 PM | Acrivon Therapeutics (1781174) Issuer Gamelin Erick (1950551) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 3:12 PM | Acrivon Therapeutics (1781174) Issuer Miller Mary (1841088) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 3:14 PM | Acrivon Therapeutics (1781174) Issuer Peterson Katharine (2022214) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/15/2026 3:38 PM | Acrivon Therapeutics (1781174) Issuer Devroe Eric (1950573) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/08/2026 8:00 AM | Acrivon Therapeutics (1781174) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/08/2026 6:30 AM | Acrivon Therapeutics (1781174) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/21/2025 4:36 PM | Acrivon Therapeutics (1781174) Subject CITADEL ADVISORS LLC (1423053) Filed by | Form SCHEDULE 13G | |
| 11/18/2025 3:28 PM | Acrivon Therapeutics (1781174) Issuer Blume-Jensen Peter (1950499) Reporting Masson Kristina (1950501) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/18/2025 3:29 PM | Acrivon Therapeutics (1781174) Issuer Devroe Eric (1950573) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/18/2025 3:30 PM | Acrivon Therapeutics (1781174) Issuer Gamelin Erick (1950551) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/18/2025 3:32 PM | Acrivon Therapeutics (1781174) Issuer Miller Mary (1841088) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/18/2025 3:33 PM | Acrivon Therapeutics (1781174) Issuer Peterson Katharine (2022214) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 3:07 PM | Acrivon Therapeutics (1781174) Subject CITADEL ADVISORS LLC (1423053) Filed by | Form SCHEDULE 13G/A | |
| 10/21/2025 3:06 PM | Acrivon Therapeutics (1781174) Issuer Miller Mary (1841088) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/03/2025 3:26 PM | Acrivon Therapeutics (1781174) Issuer Miller Mary (1841088) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/03/2025 3:28 PM | Acrivon Therapeutics (1781174) Issuer Mirza Mansoor Raza (1588389) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/25/2025 3:39 PM | Acrivon Therapeutics (1781174) Issuer Blume-Jensen Peter (1950499) Reporting Masson Kristina (1950501) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/18/2025 4:14 PM | Acrivon Therapeutics (1781174) Issuer Blume-Jensen Peter (1950499) Reporting Masson Kristina (1950501) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/13/2025 10:12 AM | Acrivon Therapeutics (1781174) Subject Sands Capital Life Sciences Pulse Fund II, L.P. (1875620) Filed by | Form SCHEDULE 13G/A | |
| 06/17/2025 7:17 PM | Acrivon Therapeutics (1781174) Issuer Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund II, L.P. (1825376) Reporting Shah Rajeev M. (1619841) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2025 4:48 PM | Acrivon Therapeutics (1781174) Issuer Magovcevic-Liebisch Ivana (1279281) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2025 4:49 PM | Acrivon Therapeutics (1781174) Issuer Palani Santhosh (2013475) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2025 4:54 PM | Acrivon Therapeutics (1781174) Issuer Shacham Sharon (1588438) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2025 4:57 PM | Acrivon Therapeutics (1781174) Issuer TOMSICEK MICHAEL JOHN (1570392) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2025 5:04 PM | Acrivon Therapeutics (1781174) Issuer DiRocco Derek (1792061) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2025 4:21 PM | Acrivon Therapeutics (1781174) Issuer BAUM CHARLES M (1579824) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/04/2025 3:05 PM | Acrivon Therapeutics (1781174) Subject PERCEPTIVE ADVISORS LLC (1224962) Filed by | Form SCHEDULE 13G/A | |
|
| 05/23/2025 3:58 PM | Acrivon Therapeutics (1781174) Issuer Blume-Jensen Peter (1950499) Reporting Masson Kristina (1950501) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/15/2025 4:24 PM | Acrivon Therapeutics (1781174) Subject CITADEL ADVISORS LLC (1423053) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2025 3:47 PM | Acrivon Therapeutics (1781174) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 05/14/2025 3:16 PM | Acrivon Therapeutics (1781174) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |